American College of Clinical Pharmacy
      Search      Cart


NIH Releases Updates on Use of Bebtelovimab

December 29, 2022

Due to the increasing prevalence of SARS-CoV-2 Omicron subvariants that are anticipated to be resistant to bebtelovimab (i.e., BQ.1, BQ.1.1, XBB), bebtelovimab is not currently authorized by the Food and Drug Administration for the treatment of COVID-19 in any region of the United States. The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of bebtelovimab for the treatment of nonhospitalized patients with COVID-19 who are at high risk of progressing to severe COVID-19.

The Panel has revised several sections of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines to reflect this recommendation, including Therapeutic Management of Nonhospitalized Adults With COVID-19 and Therapeutic Management of Nonhospitalized Children With COVID-19. For a complete list of updated sections, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.